MedPath

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)

Phase 3
Completed
Conditions
Major Depressive Disorder
Interventions
Drug: Placebo
Drug: Antidepressant Therapy (ADT)
Registration Number
NCT01715805
Lead Sponsor
Forest Laboratories
Brief Summary

The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1022
Inclusion Criteria
  • Patients who have provided consent prior to any specific procedure
  • Meet the The Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV-TR) criteria for Major Depressive Disorder (MDD)
  • Have a minimum score of 20 on 17-Item Hamilton Depression (HAMD-17) rating scale at Visits 1 and 2
Exclusion Criteria
  • Patients who do not meet DSM-IV-TR criteria for MDD

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Placebo + ADT (Double-Blind)PlaceboFollowing the 8 week ADT plus single blind placebo lead-in period participants were randomized to dose-matched placebo, once per day, oral administration plus ADT for 8 weeks (up to Week 16).
Placebo + ADT Lead-inAntidepressant Therapy (ADT)Antidepressant therapy (ADT) as prescribed by the investigator plus single-blind placebo for 8 weeks.
Placebo + ADT Lead-inPlaceboAntidepressant therapy (ADT) as prescribed by the investigator plus single-blind placebo for 8 weeks.
Placebo + ADT (Double-Blind)Antidepressant Therapy (ADT)Following the 8 week ADT plus single blind placebo lead-in period participants were randomized to dose-matched placebo, once per day, oral administration plus ADT for 8 weeks (up to Week 16).
Cariprazine + ADT (Double-Blind)Antidepressant Therapy (ADT)Following the 8 week ADT plus single blind placebo lead-in period participants were randomized to cariprazine, 1.5 to 4.5 milligrams (mg) per day, oral administration plus ADT for 8 weeks (up to Week 16).
Placebo + ADT (Continued Treatment)PlaceboFollowing the 8 week ADT plus single blind placebo lead-in period, participants who were ADT responders continued treatment with ADT plus placebo for an additional 8 weeks.
Placebo + ADT (Continued Treatment)Antidepressant Therapy (ADT)Following the 8 week ADT plus single blind placebo lead-in period, participants who were ADT responders continued treatment with ADT plus placebo for an additional 8 weeks.
Cariprazine + ADT (Double-Blind)CariprazineFollowing the 8 week ADT plus single blind placebo lead-in period participants were randomized to cariprazine, 1.5 to 4.5 milligrams (mg) per day, oral administration plus ADT for 8 weeks (up to Week 16).
Primary Outcome Measures
NameTimeMethod
Montgomery-Asberg Depression Rating Scale (MADRS) at Baseline in the Double-Blind PeriodBaseline (Week 8)

The MADRS is a clinician-rated scale to assess depressive symptomatology during the past week. Patients are rated on 10 items to assess feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating and lack of interest. Each item is scored on a 7-point scale. A score of 0 indicates the absence of symptoms, and a score of 6 indicates symptoms of maximum severity for a total possible score of 0 to 60.

Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) in the Double-Blind PeriodBaseline (Week 8) to Week 16

The MADRS is a clinician-rated scale to assess depressive symptomatology during the past week. Participants are rated on 10 items to assess feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating and lack of interest. Each item is scored on a 7-point scale. A score of 0 indicates the absence of symptoms, and a score of 6 indicates symptoms of maximum severity for a total possible score of 0 to 60. A negative change from Baseline indicates improvement. Mixed-effects model for repeated measures (MMRM) with treatment group, study center, visit, and treatment group-by-visit interaction as fixed effects, and the baseline value and baseline by-visit interaction as the covariates was used for analyses.

Secondary Outcome Measures
NameTimeMethod
Change From Baseline in Sheehan Disability Scale (SDS) Score in the Double-Blind PeriodBaseline (Week 8) to Week 16

The Sheehan Disability Scale (SDS) is a 3-item patient-rated questionnaire used to evaluate impairments in the domains of work, social life/leisure, and family life/home responsibility. All items are rated on an 11-point continuum from 0 (no impairment) to 10 (most severe). The 3 individual scores are summed for a total possible score of 0 (unimpaired) to 30 (highly impaired). A negative change from Baseline indicates improvement. MMRM with treatment group, study center, visit, and treatment group-by-visit interaction as fixed effects, and the baseline value and baseline by-visit interaction as the covariates was used for analyses.

Trial Locations

Locations (85)

Forest Investigative Site 067

🇺🇸

Bismarck, North Dakota, United States

Forest Investigative Site 018

🇺🇸

Little Rock, Arkansas, United States

Forest Investigative Site 080

🇺🇸

Redlands, California, United States

Forest Investigative Site 013

🇺🇸

Hoffman Estates, Illinois, United States

Forest Investigative Site 032

🇺🇸

Tucson, Arizona, United States

Forest Investigative Site 029

🇺🇸

Little Rock, Arkansas, United States

Forest Investigative Site 077

🇺🇸

Rockville, Maryland, United States

Forest Investigative Site 006

🇺🇸

Leesburg, Florida, United States

Forest Investigative Site 017

🇺🇸

Marietta, Georgia, United States

Forest Investigative Site 065

🇺🇸

Overland Park, Kansas, United States

Forest Investigative Site 078

🇺🇸

Redlands, California, United States

Forest Investigative Site 023

🇺🇸

Hallandale Beach, Florida, United States

Forest Investigative Site 053

🇺🇸

Fort Myers, Florida, United States

Forest Investigative Site 031

🇺🇸

Temecula, California, United States

Forest Investigative Site 074

🇺🇸

North Miami, Florida, United States

Forest Investigative Site 071

🇺🇸

Hialeah, Florida, United States

Forest Investigative Site 024

🇺🇸

Atlanta, Georgia, United States

Forest Investigative Site 062

🇺🇸

Maywood, Illinois, United States

Forest Investigative Site 068

🇺🇸

Skokie, Illinois, United States

Forest Investigative Site 070

🇺🇸

Chicago, Illinois, United States

Forest Investigative Site 036

🇺🇸

Oakland Park, Florida, United States

Forest Investigative Site 027

🇺🇸

North Miami, Florida, United States

Forest Investigative Site 033

🇵🇷

San Juan, Puerto Rico

Forest Investigative Site 028

🇺🇸

Brooklyn, New York, United States

Forest Investigative Site 045

🇺🇸

Natick, Massachusetts, United States

Forest Investigative Site 059

🇺🇸

Lincoln, Rhode Island, United States

Forest Investigative Site 052

🇺🇸

Allentown, Pennsylvania, United States

Forest Investigative Site 083

🇺🇸

New York, New York, United States

Forest Investigative Site 034

🇵🇷

San Juan, Puerto Rico

Forest Investigative Site 025

🇺🇸

Staten Island, New York, United States

Forest Investigative Site 081

🇺🇸

Bellevue, Washington, United States

Forest Investigative Site 043

🇺🇸

Seattle, Washington, United States

Forest Investigative Site 082

🇺🇸

Garden Grove, California, United States

Forest Investigative Site 085

🇺🇸

Culver City, California, United States

Forest Investigative Site 084

🇺🇸

Cerritos, California, United States

Forest Investigative Site 004

🇺🇸

Oceanside, California, United States

Forest Investigative Site 022

🇺🇸

Newport Beach, California, United States

Forest Investigative Site 090

🇺🇸

Rancho Mirage, California, United States

Forest Investigative Site 044

🇺🇸

South Miami, Florida, United States

Forest Investigative Site 072

🇺🇸

Naperville, Illinois, United States

Forest Investigative Site 042

🇺🇸

Lafayette, Indiana, United States

Forest Investigative Site 016

🇺🇸

New York, New York, United States

Forest Investigative Site 086

🇺🇸

Saint Charles, Missouri, United States

Forest Investigative Site 088

🇺🇸

Canton, Ohio, United States

Forest Investigative Site 064

🇺🇸

Middleburg Heights, Ohio, United States

Forest Investigative Site 066

🇺🇸

Mason, Ohio, United States

Forest Investigative Site 055

🇺🇸

Columbus, Ohio, United States

Forest Investigative Site 087

🇺🇸

The Woodlands, Texas, United States

Forest Investigative Site 005

🇺🇸

Houston, Texas, United States

Forest Investigative Site 030

🇺🇸

Orem, Utah, United States

Forest Investigative Site 041

🇺🇸

Charlottesville, Virginia, United States

Forest Investigative Site 057

🇺🇸

Waukesha, Wisconsin, United States

Forest Investigative Site 014

🇺🇸

Toms River, New Jersey, United States

Forest Investigative Site 019

🇺🇸

Winter Park, Florida, United States

Forest Investigative Site 060

🇺🇸

Atlanta, Georgia, United States

Forest Investigative Site 047

🇺🇸

Smyrna, Georgia, United States

Forest Investigative Site 063

🇺🇸

Libertyville, Illinois, United States

Forest Investigative Site 010

🇺🇸

Oak Brook, Illinois, United States

Forest Investigative Site 046

🇺🇸

Boston, Massachusetts, United States

Forest Investigative Site 069

🇺🇸

Wichita Falls, Texas, United States

Forest Investigative Site 051

🇺🇸

Orlando, Florida, United States

Forest Investigative Site 076

🇺🇸

Bronx, New York, United States

Forest Investigative Site 079

🇺🇸

Austin, Texas, United States

Forest Investigative Site 056

🇺🇸

Milwaukee, Wisconsin, United States

Forest Investigative Site 007

🇺🇸

San Diego, California, United States

Forest Investigative Site 054

🇺🇸

San Diego, California, United States

Forest Investigative Site 048

🇺🇸

Denver, Colorado, United States

Forest Investigative Site 050

🇺🇸

Durham, North Carolina, United States

Forest Investigative Site 026

🇺🇸

Miami, Florida, United States

Forest Investigative Site 075

🇺🇸

Miami, Florida, United States

Forest Investigative Site 008

🇺🇸

Tampa, Florida, United States

Forest Investigative Site 061

🇺🇸

Indianapolis, Indiana, United States

Forest Investigative Site 089

🇺🇸

Cincinnati, Ohio, United States

Forest Investigative Site 011

🇺🇸

Cincinnati, Ohio, United States

Forest Investigative Site 015

🇺🇸

Cincinnati, Ohio, United States

Forest Investigative Site 035

🇺🇸

Oklahoma City, Oklahoma, United States

Forest Investigative Site 038

🇺🇸

Oklahoma City, Oklahoma, United States

Forest Investigative Site 039

🇺🇸

Oklahoma City, Oklahoma, United States

Forest Investigative Site 003

🇺🇸

Portland, Oregon, United States

Forest Investigative Site 037

🇺🇸

Coral Springs, Florida, United States

Forest Investigative Site 049

🇺🇸

Gaithersburg, Maryland, United States

Forest Investigative Site 012

🇺🇸

Rockville, Maryland, United States

Forest Investigative Site 073

🇺🇸

New Orleans, Louisiana, United States

Forest Investigative Site 001

🇺🇸

Charleston, South Carolina, United States

Forest Investigative Site 058

🇺🇸

Albuquerque, New Mexico, United States

© Copyright 2025. All Rights Reserved by MedPath